LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR (NASDAQ: LNSR) has announced the granting of stock options to two newly-hired non-executive employees as employment inducements. The grants, approved by independent board members on March 3, 2025, allow the purchase of a total of 1,600 shares of common stock at $13.48 per share, matching the closing price on the grant date.
The options feature a vesting schedule where 25% vests after one year, followed by 36 monthly installments, contingent on continued employment. These 10-year term options were granted under LENSAR's 2024 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).
LENSAR (NASDAQ: LNSR) ha annunciato l'assegnazione di opzioni su azioni a due nuovi dipendenti non esecutivi come incentivo all'assunzione. Le concessioni, approvate dai membri indipendenti del consiglio il 3 marzo 2025, consentono l'acquisto di un totale di 1.600 azioni ordinarie a $13,48 per azione, corrispondente al prezzo di chiusura nel giorno della concessione.
Le opzioni prevedono un piano di maturazione in cui il 25% matura dopo un anno, seguito da 36 rate mensili, a condizione di continuare l'impiego. Queste opzioni con scadenza di 10 anni sono state concesse nell'ambito del 2024 Employment Inducement Incentive Award Plan di LENSAR e sono conformi alla Regola di Inserimento Nasdaq 5635(c)(4).
LENSAR (NASDAQ: LNSR) ha anunciado la concesión de opciones sobre acciones a dos nuevos empleados no ejecutivos como incentivos de empleo. Las concesiones, aprobadas por miembros independientes de la junta el 3 de marzo de 2025, permiten la compra de un total de 1,600 acciones ordinarias a $13.48 por acción, coincidiendo con el precio de cierre en la fecha de concesión.
Las opciones cuentan con un calendario de adquisición donde el 25% se adquiere después de un año, seguido de 36 cuotas mensuales, condicionado a la continuidad del empleo. Estas opciones con un plazo de 10 años fueron otorgadas bajo el 2024 Employment Inducement Incentive Award Plan de LENSAR y cumplen con la Regla de Cotización Nasdaq 5635(c)(4).
LENSAR (NASDAQ: LNSR)는 두 명의 신규 비임원 직원에게 고용 유인을 위해 주식 옵션을 부여했다고 발표했습니다. 이 부여는 2025년 3월 3일에 독립 이사들에 의해 승인되었으며, 총 1,600주의 보통주를 $13.48 per share에 구매할 수 있습니다. 이는 부여일의 종가와 일치합니다.
옵션은 1년 후 25%가 확정되고, 이후 36개월 동안 매월 분할되어 계속 고용되는 조건을 포함합니다. 이 10년 만기 옵션은 LENSAR의 2024 Employment Inducement Incentive Award Plan에 따라 부여되었으며, Nasdaq 상장 규정 5635(c)(4)를 준수합니다.
LENSAR (NASDAQ: LNSR) a annoncé l'octroi d'options d'achat d'actions à deux nouveaux employés non exécutifs en tant qu'incitatifs à l'embauche. Les attributions, approuvées par des membres indépendants du conseil d'administration le 3 mars 2025, permettent l'achat d'un total de 1 600 actions ordinaires au prix de $13,48 par action, correspondant au prix de clôture à la date d'attribution.
Les options comprennent un calendrier d'acquisition où 25 % sont acquises après un an, suivies de 36 versements mensuels, sous réserve de la continuité de l'emploi. Ces options d'une durée de 10 ans ont été accordées dans le cadre du 2024 Employment Inducement Incentive Award Plan de LENSAR et sont conformes à la règle de cotation Nasdaq 5635(c)(4).
LENSAR (NASDAQ: LNSR) hat die Gewährung von Aktienoptionen an zwei neu eingestellte nicht-executive Mitarbeiter als Einstellungsanreiz bekannt gegeben. Die Zuteilungen, die von unabhängigen Vorstandsmitgliedern am 3. März 2025 genehmigt wurden, ermöglichen den Kauf von insgesamt 1.600 Stammaktien zu $13,48 pro Aktie, was dem Schlusskurs am Zuteilungsdatum entspricht.
Die Optionen haben einen Vesting-Zeitplan, bei dem 25% nach einem Jahr fällig werden, gefolgt von 36 monatlichen Raten, abhängig von der Fortsetzung der Beschäftigung. Diese 10-jährigen Optionen wurden im Rahmen des 2024 Employment Inducement Incentive Award Plan von LENSAR gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 1,600 shares of the Company’s common stock. The options were granted as of March 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, which is designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth / Cameron Radinovic | |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR | |
| ir.contact@lensar.com | lroth@burnsmc.com / cradinovic@burnsmc.com |
FAQ
What are the key terms of LENSAR's (LNSR) March 2025 stock option grants?
How long is the vesting period for LENSAR's (LNSR) March 2025 inducement grants?
What is the exercise price of LENSAR's (LNSR) March 2025 inducement stock options?
When do LENSAR's (LNSR) March 2025 inducement stock options expire?
